TrialCancer immunology research2026

Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer.

Sung Hee Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.